Nina Shah, MD
Chimeric antigen receptor (CAR) T-cell therapy could bring hematologists closer to a curative strategy in multiple myeloma; however, there are still areas of refinement that need to be addressed, said Nina Shah, MD.
Mainly, researchers now know that CAR T cells are tolerable, but Shah explained there are patient concerns with the therapy’s benefit before they face financial toxicity. Efficacy data are still in preliminary stages, and numerous clinical trials are ongoing.
... to read the full story